drugset / Trial / NCT02825979

Early Aggressive Invasive Intervention for Atrial Fibrillation

NCT02825979

RandomizedParallel-groupOpen-labelTreatment

Summary

The EARLY-AF study is centered on an evaluation of the impact of the early invasive management of Atrial Fibrillation. The primary goal of the study is to evaluate the clinical effectiveness of an early invasive approach. Specifically, the investigators are aiming to evaluate if PVI performed with the Arctic Front cryoballoon is superior to AAD as first-line therapy in preventing atrial arrhythmia recurrences (arrhythmia related symptoms, hospitalisations, and health care utilization) and health care utilisation at one year of follow-up. The aim of the extended follow-up phase of the trial (PROGRESSIVE-AF) is to evaluate if the initial treatment choice (ablation vs. pharmacotherapy) influences AF disease progression, as measured by continuous cardiac monitoring. The outcomes of interest are disease progression, quality of life, and healthcare utilisation.

Timeline

Start
2017-01
Primary completion
2022-09
Completion
2022-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronedarone Small molecule
Subject flecainide Small molecule
Subject propafenone Unknown
Subject sotalol Small molecule

Indications